These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 24612551)

  • 21. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
    Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
    Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
    Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
    Závada J; Uher M; Sisol K; Forejtová Š; Jarošová K; Mann H; Vencovský J; Pavelka K
    Ann Rheum Dis; 2016 Jan; 75(1):96-102. PubMed ID: 25165033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.
    Bes C; Yazici A; Soy M
    Rheumatol Int; 2013 Jun; 33(6):1415-8. PubMed ID: 23143665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of tumor necrosis factor-alpha on sexual activity of male patients with ankylosing spondylitis.
    Dong X; Zheng Y; Shi TY; Liu HY
    Clin Rheumatol; 2015 May; 34(5):915-20. PubMed ID: 25064131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
    Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study.
    Zhang K; Zheng Y; Han Q; Liu Y; Wang W; Ding J; Wang Y; Zhang B; Jia J; Zheng M; Zheng Z; Zhu P
    Front Immunol; 2021; 12():740980. PubMed ID: 34659233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis.
    Korkosz M; Gąsowski J; Surdacki A; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
    Pharmacol Rep; 2013; 65(4):891-7. PubMed ID: 24145083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.
    Jeong H; Eun YH; Kim IY; Kim H; Ahn JK; Lee J; Koh EM; Cha HS
    Korean J Intern Med; 2018 Mar; 33(2):407-416. PubMed ID: 27729625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
    Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
    Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.
    Kneepkens EL; Krieckaert CL; van der Kleij D; Nurmohamed MT; van der Horst-Bruinsma IE; Rispens T; Wolbink GJ
    Ann Rheum Dis; 2015 Oct; 74(10):1825-9. PubMed ID: 24812290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases.
    Kubo Y; Ohishi M; Nakashima Y; Okazaki K; Fukushi J; Oyamada A; Iwamoto Y
    Fukuoka Igaku Zasshi; 2015 Dec; 106(12):316-22. PubMed ID: 27159947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
    Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
    Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.